Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma - Seite 3

Follow us on social media:
Facebook: https://www.facebook.com/AllarityTx/
LinkedIn: https://www.linkedin.com/company/allaritytx/
Twitter: https://twitter.com/allaritytx

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of Allarity’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning Allarity’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. Allarity undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Allarity’s clinical programs may be delayed or impacted by the ongoing global COVID-19 pandemic.

###

Investor Contact:
            Jens Knudsen, CFO  
            [phone]
            Email inquiries: [e-mail]

Media Contact:
            Thomas Pedersen
            Carrotize PR & Communications
            [phone]
            Email inquiries: [e-mail]

Certified Adviser:
Svensk Kapitalmarknadsgranskning AB, Email: [e-mail]. Tel: [phone]

This information is information that Allarity A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on 9 March 2021.

Attachment

• Allarity_Positive Data from Preclinical Dovitinib Study